KRAS and lung cancer: Some pilot studies have reported that intrinsic factors in EGFR-mutant lung cancer cells, such as mutations in T790M, PI3CA, or KRAS and activation of the intracellular Fas/NF-κB signaling pathway, may confer primary resistance to EGFR TKIs[9]–[11].